Table 1. Patient and tumor characteristics, with comparison of clinicopathological characteristics between patients with synchronous lung metastases (Group A) and patients with metachronous lung metastases (Group B).
Abbreviations: LDH, lactate dehydrogenase; ALP, alkaline phosphatase; ULNL, upper limit of normal level; CT, Chemotherapy.
| No. of patients (%) | ||||
| Variable | All patients (n = 93) | Group A (n = 39) | Group B (n = 54) | P |
| Gender | 0.906 | |||
| Female / Male | 28 (30.1) / 65 (69.9) | 12 (30.8) / 27 (69.2) | 16 (29.6) / 38 (70.4) | |
| Age | 0.564 | |||
| <18 years | 28 (30.1) | 13 (33.3) | 15 (27.8) | |
| ≥ 18 years | 65 (69.9) | 26 (66.7) | 39 (72.2) | |
| Localization | 0.564 | |||
| Upper extremity | 13 (14.0) | 7 (17.9) | 6 (11.1) | |
| Lower extremity | 74 (79.6) | 29 (74.4) | 45 (83.3) | |
| Trunk | 6 (6.5) | 3 (7.7) | 3 (5.6) | |
| Histopathological subtype | 0.593 | |||
| Osteoblastic | 44 (51.8) | 19 (54.3) | 25 (50.0) | |
| Chondroblastic | 17 (20.0) | 6 (17.1) | 11 (22.0) | |
| Fibroblastic | 8 (9.4) | 2 (5.7) | 6 (12.0) | |
| Telangiectatic | 10 (11.8) | 4 (11.4) | 6 (12.0) | |
| Others | 6 (7.1) | 4 (11.4) | 2 (4.0) | |
| Tumor size | 0.199 | |||
| ≤ 8 cm | 13 (15.9) | 3 (9.4) | 10 (20.0) | |
| > 8 cm | 69 (84.1) | 29 (90.6) | 40 (80.0) | |
| LDH | 0.132 | |||
| Normal | 33 (48.5) | 11 (37.9) | 22 (56.4) | |
| High | 35 (51.5) | 18 (62.1) | 17 (43.6) | |
| ALP | 0.012 | |||
| Normal | 35 (43.2) | 9 (25.7) | 26 (56.5) | |
| High (< 4 x ULNL) | 28 (34.6) | 14 (40.0) | 14 (30.4) | |
| High (≥ 4 x ULNL) | 18 (22.2) | 12 (34.3) | 6 (13.0) | |
| Surgery for primary tumor | 0.386 | |||
| No | 17 (18.3) | 13 (33.3) | 4 (7.4) | |
| Yes | 76 (81.7) | 26 (66.7) | 50 (92.6) | |
| Type of primary tumor surgery | 0.155 | |||
| Limb-Sparing | 29 (38.2) | 7 (26.9) | 22 (44.0) | |
| Amputation | 46 (60.5) | 18 (69.2) | 28 (56.0) | |
| Others | 1 (1.3) | 1 (3.9) | ||
| Percentage of necrosis (primary site) | 0.100 | |||
| Necrosis ≥ 90% (Good) | 5 (12.5) | 0 | 5 (17.9) | |
| Necrosis 60–89% (Fair) | 8 (20.0) | 4 (33.3) | 4 (14.3) | |
| Necrosis < 60% (Poor) | 27 (67.5) | 8 (66.7) | 19 (67.9) | |
| Laterality of lung metastases | 0.234 | |||
| Bilateral | 57 (64.0) | 27 (71.1) | 30 (58.8) | |
| Unilateral | 32 (36.0) | 11 (28.9) | 21 (41.2) | |
| Number of lung metastases | 0.915 | |||
| ≤ 3 lesions | 28 (32.2) | 12 (31.6) | 16 (32.7) | |
| > 3 lesions | 59 (67.8) | 26 (68.4) | 33 (67.3) | |
| Size of largest lung nodules | 0.001 | |||
| ≤ 1 cm | 21 (29.6) | 15 (51.7) | 6 (14.3) | |
| > 1 cm | 50 (70.4) | 14 (48.3) | 36 (85.7) | |
| Presence of nonpulmonary metastases | 0.006 | |||
| None (lung only) | 71 (76.3) | 35 (89.7) | 36 (66.7) | |
| Lung and local recurrence | 12 (12.9) | 0 | 12 (22.2) | |
| Lung and bone | 10 (10.8) | 4 (10.3) | 6 (11.1) | |
| Presence of lung metastasectomy | 0.943 | |||
| Present | 21 (24.7) | 9 (24.3) | 12 (25.0) | |
| Absent | 64 (75.3) | 28 (75.7) | 36 (75.0) | |
| No. of patients (%) | ||||
| Variable | All patients (n = 93) | Group A (n = 39) | Group B (n = 54) | P |
| Presence of CT for lung metastases | <0.001 | |||
| Present | 53 (63.9) | 32 (84.2) | 21 (46.7) | |
| Absent | 30 (36.1) | 6 (15.8) | 24 (53.3) | |
| Treatment Modalities | 0.001 | |||
| None | 34 (37.8) | 7 (17.9) | 27 (52.9) | |
| CT only | 35 (38.9) | 23 (59.0) | 12 (23.5) | |
| Surgery only | 3 (3.3) | 0 (0.0) | 3 (5.9) | |
| Surgery + CT | 18 (20.0) | 9 (23.1) | 9 (17.6) | |